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Background: Polymyalgia rheumatica (PMR) may create some difficulties in the differential diagnosis of
elderly-onset rheumatoid arthritis (EORA) and of EORA with PMR-like onset (EORA/PMR).
Aim: To investigate possible differences between three groups of patients, with regard to serum levels of
inflammatory cytokines and steroidal hormones at baseline and after 1 month of treatment with
glucocorticoids (prednisone 7.5–12.5 mg/day).
Patients and methods: 14 patients with PMR, 15 with EORA and 14 with EORA/PMR, as well as 15
healthy, matched controls were analysed. Tumour necrosis factor a (TNFa), interleukin (IL)6, IL1 receptor
antagonist (IL1Ra), cortisol, dehydroepiandrosterone sulphate (DHEAS) and 17-hydroxy-progesterone
(PRG) were evaluated.
Results: Serum levels of both TNFa and IL6 were significantly higher in all three groups of patients than in
controls (p,0.01). Serum IL6 levels were significantly higher in patients with both PMR and EORA/PMR
than in patients with EORA (p,0.05). IL1Ra serum levels were significantly higher in patients with EORA
than in controls (p,0.001) and in patients with PMR and EORA/PMR (p,0.05). DHEAS was significantly
lower in patients with EORA/PMR than in those with EORA (p,0.05). PRG was significantly higher in all
patient groups (p,0.05). After glucocorticoid treatment, serum TNFa and IL6 levels significantly
decreased in all patient groups; IL1Ra significantly increased in patients with PMR and in those with
EORA/PMR; cortisol, DHEAS, and PRG significantly decreased in patients with PMR and in those with
EORA/PMR (p,0.05).
Conclusions: Different cytokine and steroidal hormone patterns suggest that patients with PMR and those
with EORA/PMR seem to be have a more intensive inflammatory reaction and are more efficient
responders to glucocorticoid treatment than patients with EORA.
P
olymyalgia rheumatica (PMR) is an inflammatory
condition of unknown aetiology characterised by pain
and stiffness in the shoulder and in the pelvic girdle.
PMR occurs in people aged .50 years and usually responds
rapidly to low doses of glucocorticoids and has a favourable
prognosis.1 2 Genetic causes and polymorphisms of additional
genes associated with the initiation and regulation of
inflammatory reaction have been considered possible sus-
ceptibility factors for PMR.3 4 In particular, polymorphisms of
tumour necrosis factor a (TNFa), and interleukin 1 receptor
antagonist (IL1Ra) genes are predisposing factors and may be
implicated in the pathogenesis of PMR.5–7 On the other hand,
increased production of interleukin (IL)6 is a characteristic
finding in patients with PMR, and glucocorticoids rapidly
reduce serum levels of IL6.8–10 The suppression of the
hypothalamic–pituitary–adrenal axis and ageing may con-
tribute to the pathogenesis of PMR. Ageing is accompanied
by marked changes in steroid hormone levels, and the age-
related increase of cytokines such as IL6 may modulate the
endocrine system. Recently, a reduced production of adrenal
hormones, such as cortisol and dehydroepiandrosterone
sulphate (DHEAS), has been shown in patients with
untreated PMR with active disease, as well as an increased
17-hydroxy-progesterone (PRG) production after adreno-
corticotropic hormone (ACTH) testing.10 11
The occurrence of peripheral arthritis, particularly in both
hands, may create some difficulties in the differential
diagnosis between PMR and elderly-onset rheumatoid
arthritis (EORA).12 Symmetrical peripheral involvement,
rheumatoid factor seropositivity, development of joint ero-
sions and extra-articular manifestations differentiate rheu-
matoid arthritis from PMR.1 13 14 Anti-cyclic citrullinated
peptide antibodies may also be useful in the differential
diagnosis between PMR and EORA.15 However, several
patients with seronegative EORA show a relatively mild
symmetric synovitis, characterised by a rapid and complete
response to glucocorticoids and a non-erosive course.1
Symptoms and signs of both PMR and EORA may alternate
during the follow-up of the patients.16 At the beginning of the
disease, these patients show a clinical condition different
from classic rheumatoid arthritis, which more closely
resembles PMR.17–19 On the other hand, a prospective study
on clinical features of PMR and rheumatoid arthritis with
PMR-like onset showed that 20% of patients with PMR
developed overt rheumatoid arthritis during the follow-up
period.20
The aim of our study was to evaluate the possible
differences between EORA and PMR, as well as between
these clinical conditions and EORA with PMR-like onset
(EORA/PMR), with respect to some inflammatory cytokines
Abbreviations: ACTH, adrenocorticotrophic hormone; CRP, C reactive
protein; DHEAS, dehydroepiandrosterone sulphate; EORA, elderly-onset
rheumatoid arthritis; EORA/PMR, EORA with polymyalgia rheumatica-
like onset; ESR, erythrocyte sedimentation rate; IL1Ra, interleukin 1
receptor antagonist; PMR, polymyalgia rheumatica; PRG, 17-hydroxy-
progesterone; TNFa, tumour necrosis factor a
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(TNFa, IL6 and IL1Ra) and steroidal hormones (cortisol,
DHEAS and PRG). Serum levels of cytokines and steroids,
erythrocyte sedimentation rate (ESR) and the C reactive
protein (CRP) level were evaluated at baseline and 1 month
after glucocorticoid treatment.
PATIENTS AND METHODS
Patients
Of the 43 patients and 15 controls evaluated, 14 patients had
PMR (4 men and 10 women; mean (standard deviation (SD))
age 73 (4) years; mean disease duration 2.8 (2) months), 15
had EORA (4 men and 11 women; mean age 72 (6) years;
mean disease duration 3.7 (2.4) months) and 14 patients had
EORA/PMR (4 males and 10 females; mean age 70 (7) years;
mean disease duration 3.6 (2.2) months). Patients with PMR
met the criteria set out by Chuang et al.21 Patients with EORA
(disease onset after 60 years of age) had peripheral arthritis
and met at least four American College of Rheumatology
criteria for rheumatoid arthritis.22 Patients with EORA/PMR
had pain and stiffness in both shoulders and in the pelvic
girdle, together with peripheral arthritis, and met at least
four American College of Rheumatology criteria for rheuma-
toid arthritis. The patients were diagnosed the first time and
they were not treated with corticosteroids before the study.
Furthermore, no patient was taking immunosuppressive
agents before and during the study. All groups of patients
received only prednisone (7.5–12.5 mg/day), and paraceta-
mol was the only additional drug permitted for pain relief
during the study (maximum dose 3 g/day). In our clinical
practice, the starting prednisone dose in patients with PMR is
not higher than 12.5 mg/day, at least in the absence of
temporal arteritis. No patient had vasculitic symptoms, and
the lower dosage was due to the presence of patients with
diabetes mellitus or altered cardiac function. For these
reasons, the prednisone dose was between 7.5 and 12.5 mg/
day. The controls (4 men and 11 women; mean age 70 (SD
7) years) had osteoarthritis of the knee or hip, and their
routine laboratory examination results were normal. All
patients and controls gave their informed consent to be
enrolled in the study.
Cytokine and hormone assessment
At baseline, fasting blood samples were collected between
08:00 and 09:00 h. All patients were subjected to a further
blood analysis 1 month after glucocorticoid treatment. Blood
samples were centrifuged 30 min after collection. Tubes
containing serum tubes were frozen at 270 C˚ to allow all
samples to be tested at the same time.
The following cytokines and hormones were evaluated:
IL6, TNFa, IL1Ra, cortisol, DHEAS and PRG.
ELISA was used to measure serum levels of IL1Ra
(Beckman Coulter, Marseille, France), IL6 and TNFa
(Cayman, Ann Arbor, Minnesota, USA). Each kit specifically
measures both natural and recombinant human TNFa, IL6
and IL1Ra, showing no detectable cross-reaction with other
cytokines. The detection limit was 1.5 pg/ml for TNFa, 2 pg/
ml for IL6 and 30 pg/ml for IL1Ra. Intra-assay and inter-
assay coefficients of variance (CVs) were 1.97% and 3.85% for
TNFa, 2.34% and 3.86% for IL6, and 4.35% and 8.6% for
IL1Ra, respectively. The results were expressed in pg/ml.
Serum levels of cortisol and DHEAS were assayed by a
chemiluminescent method (DPC, Los Angeles, California,
Figure 1 Serum levels of tumour necrosis factor a (TNFa) (A), interleukin-6 (IL6) (B) and interleukin-1 receptor antagonist (IL1Ra) (C) in patients with
polymyalgia rheumatica (PMR), elderly-onset rheumatoid arthritis (EORA), EORA with polymyalgia-like clinical onset (EORA/PMR) and controls
(CNTR) at baseline (T0) and 1 month after glucocorticoid treatment (T1). Data are given as box plots with 5th, 10th, 50th (median), 90th and 95th
centiles. *p,0.05; **p,0.01; ***p,0.001 between groups. +p,0.05; ++p,0.01 T1 v T0.
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USA, and Nichols Institute of Diagnostics, San Juan
Capistrano, California, USA, respectively), with a detection
limit of 0.552 nmol/l for cortisol and 0.003 nmol/l for DHEAS.
CVs were 6.5% for cortisol and 6.7% for DHEAS. Serum levels
of PRG were measured by direct immunoenzymatic method
(Mascia Brunelli, Milan, Italy), with a detection limit of
0.150 nmol/l and a CV of 5.4%. The results for hormones were
reported in nmol/l. All samples were tested in triplicates.
CRP was evaluated by routine nephelometric examination
and values were expressed in mg/l. ESR was assessed
routinely by Westergren method (mm at the end of the first
hour).
Statistical analysis
Data were analysed using non-parametric Wilcoxon signed
rank test to compare the median levels of both cytokines and
hormones at different times, and Mann–Whitney U test to
compare the median levels of both cytokines and hormones
between the different groups of patients. Spearman’s rank
correlation test was used to assess possible correlations
between variables. A p value ,0.05 was considered sig-
nificant.
RESULTS
No significant difference was found between the groups with
regard to age of participants and disease duration in patients.
Serum TNFa levels were significantly higher in all three
groups of patients, but there was no statistically significant
difference for serum TNFa levels between the three groups of
patients (fig 1A). Serum IL6 levels were significantly higher
in patients with PMR, EORA/PMR, and EORA, than in
controls. Furthermore, serum IL6 levels were significantly
higher in patients with PMR and those with EORA/PMR than
in patients with EORA (fig 1B).
On the contrary, IL1Ra serum levels were significantly
higher in patients with EORA than in controls, as well as in
patients with PMR and those with EORA/PMR. We found no
significant difference regarding serum IL1Ra levels between
patients with PMR and those with EORA/PMR. In addition,
we found no statistically significant difference regarding
serum IL1Ra levels between controls and patients with PMR
and those with EORA/PMR; however, IL1Ra levels were
lower in controls (fig 1C).
We found no statistically significant difference regarding
cortisol serum levels between the four groups of participants.
However, cortisol level was slightly higher in patients with
PMR than in other groups (fig 2A). DHEAS was markedly
lower in patients with EORA/PMR than in those with EORA.
We observed no statistically significant difference regarding
DHEAS between patients with PMR and other groups
(fig 2B). PRG levels were significantly higher in all three
groups of patients than in controls, whereas no statistically
significant difference was found for PRG levels between the
three groups of patients (fig 2C). As regards to sex selection,
all groups had a similar sex ratio of patients (four male
patients in each group), and the limited number of patients
enrolled into the study did not allow for any statistical
analysis on hormone levels in both sexes in each group.
Figure 2 Cortisol (A), dehydroepiandrosterone sulphate (DHEAS) (B), and progesterone (PRG) (C) serum levels in patients with polymyalgia
rheumatica (PMR), elderly-onset rheumatoid arthritis with polymyalgia rheumatica-like onset (EORA/PMR) and controls (CNTR) at baseline (T0) and
1 month after glucocorticoid treatment (T1). Data are given as box plots with the 5th, 10th, 50th (median), 90th and 95th centiles. *p,0.05; **p,0.01
between groups. +p,0.05; ++p,0.01 T1 v T0.
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Interestingly, ESR and CRP values were significantly
higher in patients with PMR and those with EORA/PMR
than in patients with EORA (fig 3).
After 1 month of glucocorticoid treatment, several statis-
tically significant variations were observed. Serum TNFa and
IL6 levels decreased considerably in all groups of patients
(fig 1A,B). IL1Ra increased markedly in patients with PMR
and those with EORA/PMR, whereas no statistically sig-
nificant variation was observed for IL1Ra in patients with
EORA (fig 1C). Cortisol, DHEAS and PRG decreased
noticeably in patients with PMR and in those with EORA/
PMR (fig 2A–C). Finally, ESR and CRP decreased markedly in
patients with EORA/PMR after CG treatment when compared
with basal time values (fig 3A,B).
DISCUSSION
With regard to the laboratory markers of inflammation, the
present study suggests that patients with PMR and those
with EORA/PMR are affected by a stronger inflammatory
involvement than patients with EORA, as shown by their
significantly higher values of ESR, CRP and IL6. On the
contrary, IL1Ra was found to be significantly higher in
patients with EORA than in those with EORA/PMR. As IL1Ra
wields a protective effect on bone damage, the higher serum
IL1Ra levels observed in patients with EORA may support the
low erosive activity typical of the elderly subset of rheuma-
toid arthritis.23 24
Regarding patients with EORA/PMR and those with PMR,
IL6, IL1Ra and ESR values, showed a similar behaviour in the
patients with EORA at the time of the basal analysis.
However, at that time, all the analysed cytokines were
considerably higher in the three groups of patients than in
the control group.
After glucocorticoid treatment, the decrease in the inflam-
matory markers was more evident in patients with PMR, as
well as in those with EORA/PMR, than in patients with
EORA.
In particular, the decrease in TNFa, IL6, ESR and CRP was
markedly higher in patients with EORA/PMR, whereas IL1Ra
increased considerably only in patients with EORA/PMR and
those with PMR, and no statistically significant variation was
observed for patients with EORA.
No statistically significant differences were observed with
regard to cortisol levels between the three groups of patients
and the controls. The results of this study confirm the
findings of recent research showing a reduced production of
adrenal hormones (cortisol, DHEAS) at baseline in patients
with active and untreated PMR.11 The defect seemed mainly
related to altered adrenal responsiveness to ACTH stimula-
tion (ie, increased PRG), at least in untreated patients, and
1 month of glucocorticoid treatment reduced the production
of inflammatory mediators (ie, IL6) in a stable manner, an
effect which persisted after glucocorticoid tapering.11
Therefore, PMR may be considered a hypothalamic–
pituitary–adrenal axis-driven disease.10 25 Interestingly, in
the present study, the decrease in serum cortisol levels
induced after 1 month of glucocorticoid treatment was more
evident in patients with PMR and those with EORA/PMR,
suggesting higher hypothalamic–pituitary–adrenal axis
responsiveness than in patients with EORA. However, the
frequent observation of reduced cortisol and adrenal andro-
gen secretion during testing in patients with rheumatoid
arthritis not treated with glucocorticoids should clearly be
regarded as an ‘‘adrenal insufficiency’’ in the setting of a
sustained inflammatory process, as shown by high serum IL6
levels. In other words, the production of adrenal hormones
Figure 3 Erythrocyte sedimentation rate (ESR) (A) and C reactive protein (CRP) (B) in patients with polymyalgia rheumatica (PMR), elderly-onset
rheumatoid arthritis with polymyalgia rheumatica-like onset (EORA/PMR) at baseline (T0) and 1 month after glucocorticoid treatment (T1). Data are
given as box plots with the 5th, 10th, 50th (median), 90th and 95th centiles. *p,0.05 between groups. +p,0.05; ++p,0.01 T1 v T0.
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(cortisol and DHEAS) in patients with PMR was found to be
lower than IL6 or TNFa levels.26 27
Similarly, DHEAS levels were markedly lower in patients
with EORA/PMR than in controls, whereas in our study, no
statistically significant difference was detectable in patients
with PMR. The reduction in DHEAS is a general feature of
chronic inflammatory diseases.28–31 In the biosynthesis of
steroids, the enzyme 17,20-lyase (P450c17) is suppressed
both during ageing and in response to inflammatory stimuli,
such as IL1 and transcription growth factor type b1.32–36
Therefore, during ageing and under conditions of systemic
inflammation (such as PMR), the suppression may be due to
an inhibition of the adrenal 17,20-lyase, as cortisol under the
same circumstances is increased in relation to DHEAS.
Furthermore, the cytokine-induced inhibition of the sulpha-
tase reaction (DHEA/DHEAS) may also be considered.37 38
A marked increase in PRG levels in both basal condition
and after ACTH stimulation was described in patients with
recent-onset untreated PMR compared with age-matched
controls. Our results have confirmed this even in other
groups of patients (EORA and EORA/PMR).11 As PRG
represents a precursor of cortisol biosynthesis at the adrenal
level, a possible partial impairment of the enzyme 21a-
hydroxylase (P450c21) may lead to accumulation of the
precursor PRG. The reasons for a functional 21a-hydroxylase
impairment in PMR may include genetic defects, an age-
related increase of serum TNF level in healthy women, or
raised serum IL6 and TNFa levels during chronic systemic
inflammatory stimuli (ie, PMR).10 TNFa was shown to inhibit
21a-hydroxylase in adrenal cell cultures, and high concen-
trations of IL6 and TNFa have been shown to interfere with
enzymes associated with peripheral steroid hormone meta-
bolism.38 39 Furthermore, TNFa may be a blocker of the 17,20-
lyase, altering the biosynthesis of steroids and inducing the
increase in PRG levels.38
The quite similar hormonal changes observed in patients with
PMR and those with EORA/PMR may reflect a more severe
interference of the inflammatory cytokines on the steroid
hormone metabolism than in patients with EORA. The
hormonal differences may be related to the different severity
of inflammation. It seems that lower hormonal levels, as
observed in patients with EORA/PMR and those with PMR, are
negatively related to a higher inflammatory reaction that
distinguishes EORA/PMR and PMR from EORA. Therefore,
these results indicate that patients having clinical character-
istics of EORA and PMR as well should be treated as patients
with PMR, at least at the beginning of the disease. In addition,
the effects of the glucocorticoid treatment, acting as a
replacement for the reduced endogenous cortisol production,
seems again more efficient in patients with PMR and those with
EORA/PMR (ie, marked decrease in serum IL6 and PRG), than
in patients with EORA, at least in a short time (1 month).
In conclusion, patients with PMR and those with EORA/
PMR seem to be characterised by a more intensive
inflammatory reaction and seem to respond better to the
glucocorticoid treatment than patients with EORA. These
results further support a recent study suggesting that no
routine laboratory marker of inflammation allows for early
differentiation between patients with EORA/PMR and those
with persisting PMR.20
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